X4 Pharmaceuticals has dipped considerably following updated results presented in ASH suggesting that mavorixafor may not be effective as monotherapy in chronic neutropenia (excluding WHIM).
Greetings, and welcome to the X4 Pharmaceuticals Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback